"Complete Response" Reg Seeks Comment On Public Disclosure Of NDAs

The proposed rule would allow FDA to disclose the existence of an application once the sponsor has publicly disclosed it or after issuance of an approval or tentative approvable letter. The rule eliminates the use of "approvable" and "not approvable" letters.